Covered recipient · General Payments record
GLEN S GRAVES
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2018–2024
$1,999.64
- Reported across 105 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $430.22 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $179.02 | 6 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $85.20 | 3 |
| Fresenius Kabi USA, LLC | $47.44 | 2 |
| Amgen Inc. | $45.93 | 2 |
| Lilly USA, LLC | $30.47 | 1 |
| Acerta Pharma LLC | $21.83 | 1 |
| GlaxoSmithKline, LLC. | $20.33 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $30.08 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103829966 | CMS |
| ABBVIE INC. | $30.36 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103829968 | CMS |
| ABBVIE INC. | $23.55 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103829970 | CMS |
| ABBVIE INC. | $33.08 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103829972 | CMS |
| ABBVIE INC. | $27.31 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103829974 | CMS |
| ABBVIE INC. | $34.64 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103829976 | CMS |
| Amgen Inc. | $18.74 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111588558 | CMS |
| Amgen Inc. | $27.19 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111588556 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.83 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105855838 | CMS |
| Fresenius Kabi USA, LLC | $16.29 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146949490 | CMS |
| Fresenius Kabi USA, LLC | $31.15 | 07/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146949492 | CMS |
| GlaxoSmithKline, LLC. | $20.33 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116658185 | CMS |
| Lilly USA, LLC | $30.47 | 09/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135010835 | CMS |
| Novartis Pharmaceuticals Corporation | $29.72 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086930671 | CMS |
| Novartis Pharmaceuticals Corporation | $25.76 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086930679 | CMS |
| Novartis Pharmaceuticals Corporation | $29.72 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086930703 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.